27.49
3.97%
1.05
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Income Statement
Quarterly
*All numbers in millions
Period End Date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Period Length | 3 Months | 3 Months | 3 Months | 3 Months | 3 Months |
Revenues |
11,999%
211.12
|
1.745 | 4.091 | 1.641 | 1.826 |
Cost Of Revenue |
0.00%
0.598
|
0.598 | 0.598 | 0.599 | 0.651 |
Gross Profit |
18,254%
210.52
|
1.147 | 3.493 | 1.042 | 1.175 |
Operating Expenses
|
17.71%
210.18
|
178.56 | 161.19 | 147.14 | 127.99 |
Interest Income/Expense |
15.80%
23.47
|
20.27 | 20.31 | 20.59 | 20.12 |
Benefits Costs and Expenses |
43.71%
247.28
|
172.07 | 183.58 | 162.34 | 144.56 |
Costs And Expenses |
17.65%
210.78
|
179.16 | 161.78 | 147.74 | 127.99 |
Operating Income/Loss |
100.19%
0.343
|
-177.42 | -157.69 | -146.10 | -126.16 |
Nonoperating Income/Loss |
615.00%
-36.50
|
7.088 | -21.80 | -14.60 | -16.57 |
Income/Loss From Continuing Operations Before Tax |
78.77%
-36.16
|
-170.33 | -179.49 | -160.70 | -142.73 |
Income Tax Expense/Benefit |
-
|
- | - | - | - |
Income/Loss From Continuing Operations After Tax |
78.77%
-36.16
|
-170.33 | -179.49 | -160.70 | -142.73 |
Net Income/Loss
|
78.77%
-36.16
|
-170.33 | -179.49 | -160.70 | -142.73 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
56.70%
-0.944
|
-2.18 | -2.489 | -2.804 | -2.576 |
Basic Average Shares |
4,482%
178.71
|
3.9004 | 163.31 | 160.54 | 152.65 |
Diluted Average Shares |
4,482%
178.71
|
3.9004 | 163.31 | 160.54 | 152.65 |
Basic Earnings Per Share |
79.17%
-0.20
|
-0.96 | -1.08 | -0.98 | -0.92 |
Diluted Earnings Per Share |
79.17%
-0.20
|
-0.96 | -1.08 | -0.98 | -0.92 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):